Medtronic Acquires Ventor Technologies Ltd.

Medtronic, Inc. today announced its acquisition of Ventor Technologies Ltd., a developer of transcatheter heart valve technologies for the treatment of aortic valve disease.

Medtronic Targets Leadership Role in Aortic Transcatheter Valves.

Medtronic, Inc. today announced its acquisition of Ventor Technologies Ltd., a developer of transcatheter heart valve technologies for the treatment of aortic valve disease. Medtronic will acquire Ventor for a payment of $325 million.

Current standard of care for patients with aortic stenosis is open-heart valve surgery; however, many patients are ineligible for surgery because of their deteriorating health. Transcatheter valves offer a non-surgical alternative for patients who need their valve replaced but may not be good surgical candidates.

This acquisition adds two technologies to Medtronic’s transcatheter valve portfolio: a minimally invasive, surgical transapical technology and a next generation percutaneous, transfemoral technology. These complementary technologies offer compelling clinical benefit to distinctly different subsets of patients with aortic stenosis who are at high or prohibitive risk for surgery.

“The combination of Ventor Technologies and our strengths in research and development, operations, medical education and market development will improve patient outcomes and expand physician adoption among both surgeons and interventional cardiologists,” said Bill Hawkins, chairman and CEO of Medtronic.

Guy Ezekiel, M.D., president and CEO of Ventor Technologies, said, “We are delighted to be joining Medtronic, especially given our complementary expertise and shared commitment to aortic transcatheter valve technology. Together, we look forward to improving the quality of care for more than 300,000 people worldwide with severe aortic stenosis.”

In a separate release today, Medtronic announced it has signed an agreement to acquire CoreValve, Inc. CoreValve’s board and shareholders have approved the acquisition, which is subject to regulatory clearance. Together, these acquisitions represent Medtronic’s commitment to innovation in cardiovascular medicine.

Source: Medtronic

published: February 23, 2009 in: Cardio, Companies, Medtronic, News, Products, Specialty

Leave a Reply

Your email address will not be published. Required fields are marked *

Most read

Latest

^